Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients
Otty, Zulfiquer, Buhrer Skinner, Monika, Dass, Joshua, Collins, Michael, Mooi, Jennifer, Thuraisingam, Kandeepan, and Sabesan, Sabe (2011) Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia-Pacific Journal of Clinical Oncology, 7 (3). pp. 287-292.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1111/j.1743-7563.20...
AIMS: In this retrospective analysis, we describe the efficacy and tolerability of weekly cisplatin 40 mg/m(2) used in concurrent chemoradiation of head and neck cancer at the Townsville Cancer Centre.
METHODS: Review of medical records of patients who received radical chemoradiotherapy for head and neck cancer at Townsville Cancer Centre from 2003 to 2009.
RESULTS: In all 102 patients were analysed, 62 of whom had definitive chemoradiation and the remainder adjuvant chemoradiotherapy. Median follow up was 20.1 months (range 5-86 months). Overall 68.6% of patients received 5 weeks or more of planned chemotherapy. Radiotherapy interruptions occurred in four (6.4%) patients. The rate of grade 3-4 adverse events was 51% including neutropenia (18.6%), mucositis (21.8%) and dysphagia (12.9%) and 30.7% of patients needed hospital admission to manage toxicities. For definitive and adjuvant groups, estimated 3-year survival was 64.5 and 71.5%, respectively, and estimated 3-year disease-specific survival rates were 70.3 and 81.6%, respectively. The 3-year overall survival for patients who received five or more cycles of chemotherapy was 75.2%, compared to 52.6% for those receiving fewer than five cycles (P = 0.018).
CONCLUSION: Despite this is being a small retrospective study, survival figures and toxicity profiles of low dose weekly cisplatin are comparable to historical controls using high-dose regimens, hence justifying our approach. In addition, radiotherapy interruptions are minimized and cisplatin is easy to administer in outpatient settings. Future three-arm studies could include this regimen as the basis of treatment combined with targeted therapies.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||chemoradiation; cisplatin; head and neck cancer; retrospective; survival|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111205 Chemotherapy @ 50%|
11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111208 Radiation Therapy @ 50%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 100%|
|Deposited On:||22 Feb 2012 16:54|
|Last Modified:||17 May 2013 01:40|
Last 12 Months: 0
|Citation Counts with External Providers:||Web of Science: 2|
Repository Staff Only: item control page